- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Avidity Biosciences Inc (RNA)
Avidity Biosciences Inc stock price live, this page displays NASDAQ RNA stock exchange data. View the RNA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Avidity Biosciences Inc real time stock price chart below.
What Is the Avidity Biosciences Inc Stock Price Today?
The Avidity Biosciences Inc stock price today is 47.23.
What Is the Stock Symbol for Avidity Biosciences Inc?
The stock symbol for Avidity Biosciences Inc is ""RNA.""
What Stock Exchange Does Avidity Biosciences Inc Trade On?
Avidity Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Avidity Biosciences Inc a Good Stock to Buy?
Determining whether Avidity Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RNA quote. (ISIN: US05370A1088)
What Is the Avidity Biosciences Inc Stock Price Today?
The Avidity Biosciences Inc stock price today is 47.23.
What Is the Stock Symbol for Avidity Biosciences Inc?
The stock symbol for Avidity Biosciences Inc is ""RNA.""
What Stock Exchange Does Avidity Biosciences Inc Trade On?
Avidity Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Avidity Biosciences Inc a Good Stock to Buy?
Determining whether Avidity Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RNA quote. (ISIN: US05370A1088)
NASDAQ
Currency in USD
47.30
+0.25(+0.52%)
Real-time Data·
Fair Value
An estimate of a Avidity Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
46.58
47.38
52 wk Range
21.51
56.00
RNA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Avidity Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
46.5847.38
52 wk Range
21.5156.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RNA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Avidity Bio's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
67.00
Upside
+41.65%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
10 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Avidity Biosciences Inc Company Profile
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company’s pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Avidity Biosciences Inc SWOT Analysis
Innovative Therapy | Avidity Biosciences leads in developing targeted RNA therapies for rare muscle diseases, utilizing its proprietary Antibody Oligonucleotide Conjugate platform |
Pipeline Progress | Explore Avidity's three lead programs for DMD, DM1, and FSHD, with potential Biologics License Applications expected between late 2025 and late 2026 |
Market Opportunity | Delve into the substantial market potential for Avidity's therapies, with the FSHD market alone estimated at $4-5 billion and DMD Exon 44 projected at $400 million in U.S. sales |
Financial Outlook | Learn about Avidity's strong financial position with $1.4 billion in cash, providing runway into mid-2027, and analyst price targets ranging from $59 to $96 |
Compare RNA to Peers and Sector
Metrics to compare | RNA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRNAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.3x | −2.9x | −0.5x | |
PEG Ratio | 0.61 | 0.02 | 0.00 | |
Price/Book | 5.1x | 1.7x | 2.6x | |
Price / LTM Sales | 563.2x | 5.3x | 3.3x | |
Upside (Analyst Target) | 41.3% | 167.5% | 38.7% | |
Fair Value Upside | Unlock | 1.9% | 5.0% | Unlock |
Analyst Ratings
18 Buy
0 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 67.00
(+41.65% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-1.21 / -0.9562
Revenue / Forecast
3.85M / 1.48M
People Also Watch
FAQ
What Stock Exchange Does Avidity Bio Trade On?
Avidity Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Avidity Bio?
The stock symbol for Avidity Bio is "RNA."
What Is the Avidity Bio Market Cap?
As of today, Avidity Bio market cap is 6.03B.
What Is Avidity Bio's Earnings Per Share (TTM)?
The Avidity Bio EPS (TTM) is -3.57.
When Is the Next Avidity Bio Earnings Date?
Avidity Bio will release its next earnings report on 10 Nov 2025.
From a Technical Analysis Perspective, Is RNA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Avidity Bio Stock Split?
Avidity Bio has split 0 times.
How Many Employees Does Avidity Bio Have?
Avidity Bio has 391 employees.
What is the current trading status of Avidity Bio (RNA)?
As of 27 Aug 2025, Avidity Bio (RNA) is trading at a price of 47.30, with a previous close of 47.05. The stock has fluctuated within a day range of 46.58 to 47.38, while its 52-week range spans from 21.51 to 56.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.